Reaction
Nodular Regenerative Hyperplasia reporting signals
As of the last recalculation, Nodular Regenerative Hyperplasia appears in 702 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 197.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 52 | 197.4 | 198.6 |
| Nevirapine | 41 | 143.0 | 143.7 |
| Zidovudine | 39 | 91.5 | 91.8 |
| Efavirenz | 23 | 63.2 | 63.3 |
| Azathioprine | 142 | 59.7 | 59.7 |
| Oxaliplatin | 114 | 54.2 | 54.3 |
| Lamivudine Oral | 43 | 53.6 | 53.7 |
| Mercaptopurine | 29 | 51.7 | 51.8 |
| Abacavir Sulfate | 16 | 49.8 | 49.9 |
| Lamivudine | 47 | 48.3 | 48.3 |
| Thiotepa | 12 | 37.9 | 37.9 |
| Tofacitinib Citrate | 16 | 37.0 | 37.0 |
| Ritonavir 100 Mg | 18 | 36.6 | 36.7 |
| Atazanavir | 16 | 33.8 | 33.8 |
| Pertuzumab | 29 | 32.9 | 33.0 |
| Fluorouracil Cream, 0.5% | 75 | 32.5 | 32.6 |
| Fluorouracil | 75 | 32.1 | 32.1 |
| Ritonavir | 29 | 30.7 | 30.7 |
| Tenofovir Disoproxil Fumarate Tablets | 7 | 24.3 | 24.3 |
| Tacrolimus Ointment 0.1% | 79 | 21.1 | 21.1 |
| Tacrolimus Extended-Release Capsules | 79 | 21.0 | 21.0 |
| Lopinavir And Ritonavir | 9 | 19.9 | 19.9 |
| Everolimus Tablets | 11 | 19.7 | 19.8 |
| Entecavir | 7 | 17.9 | 18.0 |
| Raltegravir | 9 | 16.4 | 16.4 |
| Trastuzumab | 36 | 16.3 | 16.3 |
| Capecitabine | 42 | 14.4 | 14.4 |
| Cetuximab | 14 | 13.5 | 13.5 |
| Tenofovir Disoproxil Fumarate | 14 | 12.8 | 12.8 |
| Fam-Trastuzumab Deruxtecan-Nxki | 4 | 11.8 | 11.8 |
| Sofosbuvir | 7 | 10.6 | 10.6 |
| Abemaciclib | 7 | 10.5 | 10.5 |